Evidence map›Paper›PMID 35330634›Full record

ArticleMaterials today. Bio2022

In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy.

Jiehan Li, Guang Luo, Chuchu Zhang, Shuaiyu Long, Leiming Guo, Ge Yang, Feng Wang, Lingling Zhang, Liyang Shi, Yang Fu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. New prospects of cancer therapy based on pyroptosis and pyroptosis inducers.Apoptosis : an international journal on programmed cell death · 2024
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Application of injectable hydrogels in cancer immunotherapy.Frontiers in bioengineering and biotechnology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiehan LiSchool of Biomedical Sciences, Hunan University, Changsha, 410082, China.
Guang LuoDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Chuchu ZhangSchool of Biomedical Sciences, Hunan University, Changsha, 410082, China.
Shuaiyu LongSchool of Biomedical Sciences, Hunan University, Changsha, 410082, China.
Leiming GuoDepartment of R&D, Shanghai Creative Immune Therapeutics Co., Ltd, Shanghai, 200072, China.
Ge YangDepartment of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Feng WangDepartment of Gastroenterology, The Tenth People's Hospital of Shanghai, Tongji University, Shanghai, 200072, China.
Lingling ZhangDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Liyang ShiCollege of Biology, Hunan University, Changsha, 410082, China.
Yang FuDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yingjie ZhangSchool of Biomedical Sciences, Hunan University, Changsha, 410082, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a highly aggressive tumor located in the skin, with limited traditional therapies. In order to reduce the side effects caused by traditional administration method and amplify the killing effect of immune system against tumor cells, an in situ injectable hydrogel drug delivery system is developed for the first time which co-delivers doxorubicin (Dox) and imiquimod (R837) for the synergistic therapy of melanoma. The mechanical properties and stability of the hydrogel are characterized and the optimal doses of hydrogel and drugs are also identified. As a result, the co-delivery system effectively suppresses melanoma growth and metastatic progression both

Indexed as

Anti-tumor immune responseCell deathImmunogenic cell deathInjectable hydrogelMelanoma

Identifiers

PMID35330634
PMCPMC8938887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.